Nephro Care India share price
NSE: NEPHROCAREHealthcare Services
Nephro Care India Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2024 · Issue price ₹90
Last close ₹81.30up ₹2.40 (3.04%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹78.90.
30 Oct: open ₹78.90, high ₹82.00, low ₹78.90
52-week range of traded prices to 30 Oct 2026
₹50.05Low, 30 Mar 2026₹156.35High, 18 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹134 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,40083.9% delivered
Results
Standalone, as consolidated accounts are on record for only 1 of the last ten years; ₹ crore.Nephro Care India quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹29 Crup 9.12%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.61 Crup 60.09%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.5%
Revenue by quarter
Peak revenue ₹29 Cr, quarter to Jun 2026; lowest ₹23 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Revenue | 22.7 | 26.7 | 29.2 |
| Net profit | 0.4 | 1.0 | 1.6 |
| Net margin | 1.9% | 3.8% | 5.5% |
Standalone. The quarters from Sep 2024, the first on record, but for those filed as half years, which are below. The latest is shaded. No results on record for the quarter to Sep 2024.
| ₹ crore | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|
| Revenue | 17.7 | 28.3 | 39.3 |
| Net profit | 2.2 | 1.5 | 1.9 |
| Net margin | 12.4% | 5.1% | 4.9% |
Standalone. The half years in the same span that the quarters on record do not fully cover.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹89 Crup 92.77%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3.37 Crdown 7.42%
- Net margin
- 3.8%
Revenue by year
Peak revenue ₹89 Cr, year to Mar 2026; lowest ₹27 Cr, year to Mar 2024
Net profit by year, a loss in red
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 27.2 | 46.0 | 88.7 |
| Net profit | 4.4 | 3.6 | 3.4 |
| Net margin | 16.2% | 7.9% | 3.8% |
Standalone. Years to March. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Income from IPD ServicesIncome from IPD Services, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹43.3 Cr48.7%
- Income from OPD ServicesIncome from OPD Services, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹25.2 Cr28.4%
- Income from sale of medicines from pharmacyIncome from sale of medicines from pharmacy, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹20.4 Cr22.9%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −59.3% | −7.4% | −56.0% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Nephro Care India insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Directors and key managers2 purchases, 0 sales₹0.30 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.30 Cr
- Promoters and promoter group: no market trade
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Nephro Care India competitors and peers
Hospital, 40 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Nephro Care India in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Nephro Care India is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Asarfi HospitalASARFI | 314 | 18.83 | 3.21 | +43.2% | +57.5% | 18.7% | – | 0.00% |
 Hannah Joseph HospitalHANNAH | 250 | 22.35 | 2.57 | – | – | 11.5% | 14.9% | 1.82% |
 Aashka HospitalsAASHKA | 229 | 68.65 | 2.22 | +1.6% | +2.2% | 3.3% | – | 0.00% |
 Lotus Eye Hospital and InstituteLOTUSEYE | 227 | 1,520.37 | 3.77 | +14.1% | −77.4% | 0.2% | 0.4% | 0.00% |
 Abate As IndustriesABATEAS | 108 | 8.78 | 0.62 | – | – | 7.3% | 5.7% | 0.00% |
 Sangani HospitalsSANGANI | 86 | 28.66 | 2.09 | +404.9% | +15.5% | 7.8% | – | 0.00% |
 Maitreya MedicareMAITREYA | 85 | – | 3.02 | −2.5% | −2,152.0% | −11.3% | – | 0.00% |
 Fortis Malar HospitalsFORTISMLR | 74 | 540.74 | 2.15 | +49.3% | −97.0% | 0.4% | −4.6% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Nephro Care India announcements
Sep 2026
25 Sep · Meeting
Aug 2026
Nephro Care India share price by year
Each calendar year to 2025.Nephro Care India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 110.50 | −39.9% | 202.65 | 105.70 |
| 2024 | 184.00 | – | 360.80 | 179.55 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 5 Jul 2024.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 82.00 | 85.00 | 78.00 | 78.90 | 81.48 | 29,600 | 74.3% |
| 28 Oct 2026 | 80.00 | 81.75 | 80.00 | 80.75 | 80.87 | 4,400 | 72.7% |
| 27 Oct 2026 | 81.00 | 82.00 | 79.00 | 81.15 | 80.46 | 17,600 | 65.9% |
| 26 Oct 2026 | 83.00 | 83.00 | 79.50 | 79.80 | 80.44 | 15,600 | 74.4% |
| 23 Oct 2026 | 85.00 | 85.00 | 78.40 | 83.00 | 81.30 | 19,200 | 81.3% |
| 22 Oct 2026 | 85.50 | 85.95 | 83.60 | 85.95 | 84.45 | 10,400 | 92.3% |
| 21 Oct 2026 | 85.00 | 86.80 | 85.00 | 85.50 | 85.77 | 15,600 | 84.6% |
| 19 Oct 2026 | 88.00 | 88.00 | 85.00 | 85.00 | 85.64 | 8,800 | 81.8% |
| 16 Oct 2026 | 85.00 | 86.95 | 83.10 | 86.00 | 85.32 | 4,400 | 72.7% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- NEPHROCARE
- ISIN
- INE0SUN01013
- Industry
- Healthcare Services